Eva Hellstrom-Lindberg
Overview
Explore the profile of Eva Hellstrom-Lindberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
183
Citations
10473
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundgren S, Huuhtanen J, Keranen M, Feng X, Patel B, Ryland G, et al.
Sci Transl Med
. 2025 Feb;
17(787):eadl6758.
PMID: 40009697
Immune aplastic anemia (AA) is a life-threatening bone marrow failure disorder driven by an autoimmune T cell attack against hematopoietic stem and progenitor cells (HSPCs). However, the exact autoantigen targets...
2.
Rasmussen B, Nilsson L, Tobiasson M, Jadersten M, Garelius H, Dybedal I, et al.
Genes Chromosomes Cancer
. 2025 Feb;
64(2):e70029.
PMID: 39921387
In myelodysplastic syndromes (MDS), cytogenetic characteristics of the malignant bone marrow cells influence the clinical course. The aim of this study was to evaluate whether cytogenetics is useful to predict...
3.
Garelius H, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, et al.
Lancet Haematol
. 2025 Feb;
12(2):e128-e137.
PMID: 39909656
Background: In our previous study on erythropoiesis-stimulating agent (ESA) treatment in lower risk myelodysplastic syndromes from the European MDS (EUMDS) Registry, we showed that patients treated with ESAs had longer...
4.
Rombaut D, Sandmann S, Tekath T, Crouch S, de Graaf A, Smith A, et al.
Hemasphere
. 2025 Jan;
9(1):e70073.
PMID: 39850648
Lower risk (LR) myelodysplastic syndromes (MDS) are heterogeneous hematopoietic stem and progenitor disorders caused by the accumulation of somatic mutations in various genes including epigenetic regulators that may produce convergent...
5.
Creignou M, Sirenko M, Moura P, Mortera-Blanco T, Dimitriou M, Sander B, et al.
Ann Intern Med
. 2025 Jan;
178(2):300-304.
PMID: 39832370
No abstract available.
6.
Okuda R, Ochi Y, Saiki R, Yamanaka T, Terao C, Yoshizato T, et al.
Leukemia
. 2024 Dec;
39(3):760-764.
PMID: 39715854
No abstract available.
7.
Prummel K, Woods K, Kholmatov M, Schmitt E, Vlachou E, Poschmann G, et al.
bioRxiv
. 2024 Dec;
PMID: 39651275
Somatic mutations in hematopoietic stem/progenitor cells (HSPCs) can lead to clonal hematopoiesis of indeterminate potential (CHIP), potentially progressing to myelodysplastic syndromes (MDS). Here, we investigated how CHIP and MDS remodel...
8.
Crisa E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymaki M, et al.
Leukemia
. 2024 Aug;
38(10):2259-2265.
PMID: 39103678
Lenalidomide (LEN) can induce red blood cell-transfusion independence (RBC-TI) in 60-70% of del(5q) myelodysplastic neoplasm (MDS) patients. Current recommendation is to continue LEN in responding patients until failure or progression,...
9.
Orsmark-Pietras C, Lyander A, Ladenvall C, Hallstrom B, Staffas A, Awier H, et al.
Genes Chromosomes Cancer
. 2024 Jul;
63(7):e23257.
PMID: 39031442
Gene panel sequencing has become a common diagnostic tool for detecting somatically acquired mutations in myeloid neoplasms. However, many panels have restricted content, provide insufficient sensitivity levels, or lack clinically...
10.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H, et al.
Blood
. 2024 Jul;
144(15):1617-1632.
PMID: 38958467
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current...